# Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder

> **NCT07741331** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Chengdu Kanghong Pharmaceutical Group Co., Ltd.** · enrollment: 326 (estimated)

## Conditions studied

- Major Depressive Disorder (MDD)

## Interventions

- **DRUG:** KH607 tablets
- **DRUG:** Vortioxetine Hydrobromide Tablets
- **DRUG:** Part B: KH607

## Key facts

- **NCT ID:** NCT07741331
- **Lead sponsor:** Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 326 (ESTIMATED)
- **Last updated:** 2026-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741331, "Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*